PACAP-38 (Pituitary Adenylate Cyclase-Activating Polypeptide 38) is a 38-amino acid neuropeptide that has garnered significant attention in research and biohacking communities for its potent neuromodulatory and anti-inflammatory properties. As a member of the secretin/glucagon/VIP superfamily, PACAP-38 is naturally expressed throughout the nervous system, pituitary gland, adrenal glands, and gonads, where it regulates critical physiological processes including stress response, immune function, energy metabolism, and circadian rhythm entrainment.
Unlike its truncated counterpart PACAP-27, PACAP-38 is approximately 1,000-fold more potent at PAC1 receptors, making it the predominant endogenous form of this neuropeptide. While PACAP-38 is not approved for therapeutic use and remains an experimental research compound, emerging evidence from animal models, mechanistic studies, and limited human investigations suggests potential applications across diverse health domains—from neuroprotection and migraine modulation to metabolic regulation and immune support.
This article provides a comprehensive, evidence-based overview of PACAP-38's mechanisms, purported benefits, dosing protocols, and safety considerations.
PACAP-38 exerts its biological effects through three distinct G-protein coupled receptors:
PAC1 Receptor (highly selective, Gs and Gq coupled)
- Activates adenylate cyclase, elevating intracellular cAMP
- Triggers phospholipase C, generating IP3 and DAG to mobilize intracellular calcium
- Leads to robust activation of protein kinase A (PKA) and MAPK/ERK signaling cascades
VPAC1 and VPAC2 Receptors (shared with VIP, Gs coupled)
- Primarily activate adenylate cyclase and increase cAMP
- Support broader neuroendocrine signaling across multiple tissues
These signaling pathways converge on several key physiological outcomes:
- Neuronal survival and neuroprotection: PACAP-38 upregulates brain-derived neurotrophic factor (BDNF), inhibits apoptosis through Bcl-2 upregulation, and suppresses caspase-3 activity
- HPA axis modulation: PACAP-38 regulates hypothalamic-pituitary-adrenal axis activity, affecting cortisol and stress-related hormone release
- Catecholamine release: Stimulates epinephrine and norepinephrine secretion from the adrenal medulla
- Circadian rhythm regulation: Acts as the exclusive neurotransmitter in retinohypothalamic tract neurons, relaying light information to the suprachiasmatic nucleus for circadian entrainment
This multi-modal mechanism of action explains why PACAP-38 has been investigated across numerous health domains, though evidence quality varies significantly by application.
PACAP-38 shows mechanistic promise for metabolic regulation and body composition through effects on hypothalamic appetite centers, but no human randomized controlled trials demonstrate that PACAP-38 supplementation reduces body fat or weight.
Key Findings:
- PACAP neuronal ablation in the ventromedial hypothalamus increased energy intake and meal frequency while decreasing energy expenditure in lean animal models; effects were reversed in obese females, suggesting sex-dependent metabolic effects
- PAC1 receptor knockdown in POMC neurons (which regulate satiety) diminished PACAP-induced neuronal firing and reduced oxygen consumption increases by lowering CO2 production and O2 consumption
Interpretation: While animal data suggests PACAP affects appetite signaling and energy expenditure through hypothalamic pathways, human efficacy remains unproven.
Evidence for PACAP-38 in muscle hypertrophy is limited to a single animal study and in-vitro research, with no human clinical trials demonstrating efficacy for muscle growth.
Key Findings:
- In chick embryos, blocking PACAP with PACAP6-38 suppressed green light-induced satellite cell proliferation and mitotic activity
- PACAP-38 and PACAP6-38 accelerate actin polymerization in vitro, suggesting potential effects on muscle cytoskeletal dynamics
- PACAP's role in neurogenesis may indirectly support neuromuscular function, though this has not been directly tested in humans
Interpretation: Theoretical mechanisms exist, but direct evidence of muscle growth promotion in humans is absent.
PACAP-38 demonstrates neuroprotective and nerve regeneration-promoting effects in multiple animal models and limited human observational studies, but human clinical efficacy for injury recovery remains largely unproven.
Key Findings:
- In guinea pigs with facial nerve injury, PACAP treatment accelerated compound muscle action potential (CMAP) appearance from 2 weeks post-injury to just 1 week, and increased myelinated fiber count at 4 weeks
- PACAP-deficient mice showed larger cerebral infarct volumes after ischemic stroke and delayed axonal regeneration compared to wild-type controls, demonstrating that endogenous PACAP is protective
Interpretation: Strong mechanistic evidence supports nerve regeneration in animal models, but translation to human clinical outcomes requires controlled trials.
PACAP-38 shows promise for joint health based on consistent animal chondroprotective effects and two small human observational studies, though no human randomized controlled trials confirm efficacy.
Key Findings:
- Synovial fluid PACAP concentrations were significantly lower in osteoarthritis patients compared to healthy controls, with levels negatively correlating to Kellgren-Lawrence radiographic grades and pain scores
- In 72 ACL-injured patients, synovial PACAP levels were decreased in those with worse cartilage histopathology (modified Mankin scores), suggesting PACAP may reflect post-traumatic osteoarthritis severity
Interpretation: Lower PACAP levels associate with joint damage, implying potential protective roles, but causative evidence is lacking.
PACAP-38 demonstrates anti-inflammatory properties in preclinical and observational studies, but evidence in humans is limited to observational data and one small cardiac outcomes study without inflammation-specific endpoints.
Key Findings:
- In mouse BV2 microglial cells, PACAP attenuated LPS-induced IL-1β, IL-6, iNOS, and Itgam expression (p < 0.001) and reversed soma enlargement compared to LPS alone
- In STEMI patients, plasma PACAP-38 was significantly elevated before percutaneous coronary intervention and decreased post-PCI, with negative correlation to troponin levels
Interpretation: Potent anti-inflammatory effects in cell culture and animal models, but human anti-inflammatory efficacy remains unproven.
PACAP-38 shows neuroprotective effects in multiple animal models of cognitive impairment and neurodegeneration, but clinical evidence in humans is absent. Only one human observational study examining PACAP as a downstream target exists.
Key Findings:
- In rats administered an intraperitoneal PACAP-related peptide (OM-LV20), cerebral ischemia/reperfusion infarct area was reduced, behavioral abnormalities improved, and cortical/hippocampal neurons were protected
- In diabetic mice with cognitive impairment, a Mas agonist improved synaptic dysfunction and memory deficits via PACAP as a downstream target, with FOXO1 directly binding the PACAP promoter region
Interpretation: Strong mechanistic support in animal models, but human cognitive benefits remain theoretical.
PACAP-38 shows promise for mood and stress-related disorders based on strong mechanistic evidence and genetic association data, but there are zero human randomized controlled trials demonstrating efficacy.
Key Findings:
- Meta-analysis of 9 studies: the rs2267735 C allele in the ADCYAP1R1 gene (encoding PAC1 receptor) was associated with increased PTSD risk (OR=1.210, 95% CI [1.007, 1.454], p=0.042), with stronger effects in women (OR=1.328, p=0.031) versus men (OR=0.964, non-significant)
- PAC1 receptor antagonist treatment produced antidepressant-like effects in acute stress mouse models, with positioning as a potential therapy for treatment-resistant depression
Interpretation: Genetic and preclinical data support PACAP's role in stress pathophysiology, but human therapeutic trials are needed.
PACAP-38 is involved in circadian rhythm regulation and light entrainment to the suprachiasmatic nucleus, but no human evidence demonstrates that PACAP-38 improves sleep quality or duration.
Key Findings:
- PACAP is the exclusive neurotransmitter in retinohypothalamic tract neurons that mediate light information to the SCN circadian clock in mammals
- PACAP knockout mice exhibit altered responsiveness to light-induced circadian phase-shifts compared to wild-type controls
Interpretation: Essential for circadian function mechanistically, but supplementation has not been tested for human sleep improvement.
PACAP-38 shows plausible neuroprotective and anti-aging potential in multiple animal models, but lacks human randomized controlled trial evidence for longevity.
Key Findings:
- PACAP-deficient knockout mice displayed premature aging phenotypes including retinal changes, corneal keratinization, systemic amyloidosis, increased apoptosis, oxidative stress, and neuroinflammation—all reversible aging biomarkers in animal models
- Exogenous PACAP38 administration reversed age-related memory decline in aged pond snails (Lymnaea stagnalis), restoring learning capacity when endogenous PACAP levels were depleted
Interpretation: Compelling mechanistic evidence in invertebrates and rodents, but human lifespan studies are absent.
PACAP-38 shows immunomodulatory and anti-inflammatory effects in multiple animal and in-vitro models, but clinical efficacy in humans for immune support remains unproven. Only two human observational studies exist.
Key Findings:
- Lower PACAP-38 levels in multiple myeloma patients compared to healthy controls; higher levels predicted longer survival and higher probability of complete response
- PAC1-receptor agonists prevented cisplatin-induced immunosuppression and preserved bone marrow hematopoiesis during chemotherapy in observational data
Interpretation: Immunomodulatory potential suggested by biomarker data, but causative immune-boosting benefits undemonstrated.
PACAP-38 has not been demonstrated to improve athletic performance or energy in any human studies. The single human randomized controlled trial found that aerobic exercise training—despite being expected to modulate PACAP—did not actually alter serum PACAP levels.
Key Findings:
- In 45 humans: moderate-intensity and high-intensity aerobic training both significantly reduced migraine headache intensity, frequency, and duration (p<0.001), but neither training protocol altered serum PACAP levels (p=0.712) or Substance P levels (p=0.249)
- In rats, moderate physical activity induced upregulation of PACAP and PAC1R expression in dentate gyrus and cerebellar cortex, suggesting involvement in exercise-induced neurogenesis, but this has not translated to human performance data
Interpretation: No evidence supports PACAP supplementation for athletic performance. This is the lowest evidence category in the research literature.
PACAP-38 has been studied in human trials for skin-related conditions, showing measurable vascular and inflammatory effects, but evidence remains limited to a small number of human studies without replication.
Key Findings:
- PACAP-38 infusion (10 pmol/kg/min) in 35 rosacea patients increased facial skin blood flow by 90% and dilated the superficial temporal artery by 56%, with prolonged flushing and facial edema observed
- Sumatriptan reduced PACAP-38-induced facial skin blood flow for 50 minutes, constricted the superficial temporal artery for 80 minutes, and reduced flushing/edema duration
Interpretation: PACAP is a potent vasodilator in skin circulation, establishing it as a migraine and flushing trigger rather than a therapeutic for skin health.
PACAP shows potential mechanisms for supporting gut health through neuropeptide signaling, but no human clinical trials demonstrate efficacy for gut health outcomes.
Key Findings:
- PACAP increases localized Ca2+ transient frequency and amplitude in murine colonic smooth muscle cells via cAMP-dependent signaling
- NSAID-induced stress increased PACAP expression by 76% in porcine jejunal neurons, suggesting a regulatory response to gastrointestinal stress
Interpretation: Mechanistic evidence suggests GI regulatory roles, but clinical benefit in humans is unproven.
PACAP-38 shows cardioprotective properties in translational studies and is altered in myocardial infarction patients, but efficacy as a heart health therapeutic remains unproven in humans.
Key Findings:
- In STEMI patients, plasma PACAP-38 was significantly elevated before percutaneous coronary intervention and decreased after PCI, with significant negative correlation to troponin levels
- In a porcine myocardial infarction model, tissue PACAP-38 levels were significantly lower in non-ischemic left ventricle regions compared to ischemic regions
Interpretation: Altered in cardiac injury states, suggesting a biomarker role, but therapeutic benefit is undemonstrated.
PACAP-38 shows protective effects against liver ischemia-reperfusion injury in animal models, but evidence is limited to rodent studies with no human clinical trials.
Key Findings:
- PACAP-38 treatment in mice reduced hepatocellular damage and preserved liver tissue architecture after 90 minutes of warm ischemia followed by reperfusion, with diminished serum ALT levels
- PACAP-deficient mice showed exacerbated liver injury in ischemia-reperfusion models, demonstrating that endogenous PACAP is protective
Interpretation: Strong mechanistic support in rodent hepatoprotection, but no human liver health studies exist.
PACAP-38 shows consistent effects on multiple hormonal systems in animal models and isolated cell studies, but no human trials exist demonstrating clinical benefit for hormonal balance.
Key Findings:
- PACAP-38 stimulated insulin secretion in a glucose- and dose-dependent manner in rat pancreatic β-cells, with effects mediated by PAC1 receptor activation and suppressed by inhibition of adenylyl cyclase or PKA
- PACAP induced prolactin mRNA expression and secretion in grass carp pituitary cells via PAC1 receptor-dependent cAMP/PKA signaling; effects were blocked by PACAP antagonist but not VIP antagonist
Interpretation: Robust endocrine signaling in animal models, but human hormonal effects remain unproven.
PACAP-38 shows consistent biological effects on male sperm function in human and animal studies, but evidence of actual clinical efficacy for sexual health is limited.
Key Findings:
- In 163 men, lower PACAP protein levels in seminal plasma of subfertile men compared to fertile controls; subfertile men showed reduced sperm count, motility, and vitality (p<0.001)
- PACAP addition to low-motility sperm samples in vitro increased progressive motility and rapid sperm movement
Interpretation: PACAP shows associations with sperm function and observed in-vitro benefits, but clinical fertility trials are absent.
PACAP-38 is administered via two primary routes: injection and nasal application.
Injection Protocol:
- Dose: 1-4 mcg/kg per administration, typically 100-300 mcg for a 75 kg individual
- Frequency: 2-3 times per week
- Considerations: Rapid onset of cardiovascular effects; requires sterile administration
Nasal Protocol:
- Dose: 100-300 mcg per nostril, delivering 200-600 mcg total
- Frequency: Once daily or every other day
- Considerations: May bypass some systemic cardiovascular effects compared to injection; absorption may be variable
Most research contexts employ injection for bioavailability consistency, though nasal administration is gaining interest for convenience and potentially reduced systemic vasodilation.
PACAP-38 is an experimental